Market Cap 6.32B
Revenue (ttm) 0.00
Net Income (ttm) -505.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,699,700
Avg Vol 1,948,906
Day's Range N/A - N/A
Shares Out 205.31M
Stochastic %K 38%
Beta 0.76
Analysts Strong Sell
Price Target $45.76

Company Profile

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovan...

Industry: Biotechnology
Sector: Healthcare
Phone: 917 410 3120
Address:
1000 Park Forty Plaza, Suite 210, Durham, United States
NVDAMillionaire
NVDAMillionaire Jun. 5 at 6:34 PM
$IMVT Great piece that accurately captures IMVT's current position. So if you want to refresh your understanding of IMVT or learn about IMVT for the first time, this is essential reading. https://everyticker.com/quote/IMVT/analysis/immunovant-s-7-billion-bet-can-imvt-1402-s-best-in-class-profile-justify-a-pipeline-in-a-product-valuation-nasdaq-imvt
0 · Reply
anachartanalyst
anachartanalyst May. 26 at 2:01 PM
$IMVT https://anachart.com/wp-content/uploads/2026/05/1779804088_soc-img.jpg
0 · Reply
jcooptechit
jcooptechit May. 22 at 4:56 PM
$CUE | CATALYST TIMELINE IS STACKING 🔥 Cue Biopharma is entering a major value-driving window with multiple 2H 2026 milestones ahead. ▫️ CUE-221 Phase 2 China data expected 2H 2026 ▫️ Food allergy IND amendment planned ▫️ CUE-401 IND filing expected 2H 2026 ▫️ Phase 1 first-in-human targeted by year-end ▫️ $7.5M Boehringer milestone validates the platform ▫️ $30M financing strengthens execution This is now a clinical-stage immunology/allergy story with big catalysts lining up. Keep CUE on close watch going into data. 🧐 Communicated - Disclaimer: https://stockresearchtoday.com/cue/ Sector Peers: $IMVT $KYTX $CABA $TERN
1 · Reply
ShadowBanningIsBad
ShadowBanningIsBad May. 22 at 4:32 PM
$MS $DDOG $IMVT $NXPI $VLO Remember sell high buy low.
1 · Reply
Clev21
Clev21 May. 21 at 7:24 PM
$IMVT she’s consolidating right now. Big move coming after hours
0 · Reply
KenCowboys
KenCowboys May. 21 at 2:59 PM
$IMVT trimmed just a little yesterday at $34 but will def add some back if it drops further
0 · Reply
secondideas
secondideas May. 21 at 2:51 PM
$IMVT dilution offering
0 · Reply
Quantumup
Quantumup May. 21 at 2:25 PM
TD Cowen⬆️ $ROIV's PT to $41 and reiterated at Buy. $IMVT $ABUS TD Cowen said—IMVT-1402 Shines In D2T RA, Many More Catalysts On Deck IMVT-1402 toplined impressive Ph2b D2T RA data w/ACR20 of 73%, ACR50 of 55%, and ACR70 of 36%. Brepo in CS received FDA BTD, on track to initiate Ph3 in H2:26. Brepo DM launch in late Sept, with our KOL anticipating bolus at launch. Next catalysts: brepo Ph3 data in NIU & mosli Ph2b data in PH-ILD in H2:26. Commercial launch of IMVT-1402 in Graves' & D2T RA expected in '27/28. New PT $41 (+$3).
2 · Reply
GlobalMarketBulletin
GlobalMarketBulletin May. 21 at 10:46 AM
$IMVT Immunovant Inc. (NASDAQ: IMVT) exploded more than 35% after strong IMVT-1402 rheumatoid arthritis trial results excited biotech investors. With bullish analyst support and more updates expected in 2026, IMVT suddenly became one of the hottest healthcare stocks to watch. https://globalmarketbulletin.com/can-immunovant-imvt-turn-its-rheumatoid-arthritis-trial-win-into-a-bigger-fda-story/
0 · Reply
Quantumup
Quantumup May. 21 at 10:33 AM
BofA⬆️ $IMVT's PT to $43 and reiterated at Buy $ROIV $ARGX JNJ LLY - INCY ABBV UCBJY AZN BofA said: We raise our Immunovant (IMVT) PO to $43/sh (from $32) on a higher peak sales outlook for IMVT-1402, now $6.8BN (vs. $5.5BN prior), driven by greater contribution from GD & D2T RA-both large 'white-space' TAMs. Our revision incorporates DT2A derisking from Period 1 data (reported yesterday) and potential upside from upcoming pivotal readouts. We are most bullish on GD (50% of valuation) given strong prior data and unmet need. While CLE/SJD are sizable markets, we assign lower value due to higher clinical/competitive risk. We also reduce 1402 peak sales in FcRn-entrenched markets (MG, CIDP). See Exhibit 1 for updated risk-adjusted SOTP DCF. We reiterate Buy as in our view 1402's opportunity remains underappreciated.
0 · Reply
Latest News on IMVT
Immunovant price target raised to $47 from $35 at JPMorgan

2026-05-26T17:57:21.000Z - 14 days ago

Immunovant price target raised to $47 from $35 at JPMorgan


Immunovant price target raised to $62 from $44 at Guggenheim

2026-05-26T11:07:38.000Z - 14 days ago

Immunovant price target raised to $62 from $44 at Guggenheim


Immunovant price target raised to $30 from $23 at Truist

2026-05-22T14:20:05.000Z - 18 days ago

Immunovant price target raised to $30 from $23 at Truist


Immunovant price target raised to $43 from $32 at BofA

2026-05-21T11:27:33.000Z - 19 days ago

Immunovant price target raised to $43 from $32 at BofA


Immunovant rises 33.6%

2026-05-20T16:06:43.000Z - 20 days ago

Immunovant rises 33.6%


This Is Why Immunovant Stock (IMVT) Is Up Today

2026-05-20T15:38:53.000Z - 20 days ago

This Is Why Immunovant Stock (IMVT) Is Up Today


Immunovant rises 25.9%

2026-05-20T14:00:42.000Z - 20 days ago

Immunovant rises 25.9%


Immunovant Earnings Call Transcript: Q4 2026

May 20, 2026, 8:00 AM EDT - 20 days ago

Immunovant Earnings Call Transcript: Q4 2026


Immunovant Earnings release: Q4 2026

May 20, 2026, 8:00 AM EDT - 20 days ago

Immunovant Earnings release: Q4 2026


Immunovant Annual report: Q4 2026

May 20, 2026, 8:00 AM EDT - 20 days ago

Immunovant Annual report: Q4 2026


Immunovant reports Q4 EPS (73c), consensus (63)

2026-05-20T11:12:51.000Z - 20 days ago

Immunovant reports Q4 EPS (73c), consensus (63)


Immunovant Slides: Corporate presentation

May 20, 2026, 7:00 AM EDT - 20 days ago

Immunovant Slides: Corporate presentation


Immunovant price target lowered to $50 from $52 at Leerink

2026-04-02T15:31:15.000Z - 2 months ago

Immunovant price target lowered to $50 from $52 at Leerink


Immunovant Transcript: Study result

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Immunovant Transcript: Study result


Immunovant Press release: Study result

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Immunovant Press release: Study result


Immunovant Slides: Study result

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Immunovant Slides: Study result


Immunovant's treatment for eye disease fails late-stage trial

Apr 2, 2026, 5:06 AM EDT - 2 months ago

Immunovant's treatment for eye disease fails late-stage trial


Immunovant initiated with a Market Perform at Bernstein

2026-03-19T20:22:48.000Z - 2 months ago

Immunovant initiated with a Market Perform at Bernstein


Immunovant price target raised to $23 from $22 at Truist

2026-02-09T12:25:15.000Z - 4 months ago

Immunovant price target raised to $23 from $22 at Truist


Immunovant price target raised to $44 from $41 at Guggenheim

2026-02-09T11:52:26.000Z - 4 months ago

Immunovant price target raised to $44 from $41 at Guggenheim


Immunovant Earnings Call Transcript: Q3 2026

Feb 6, 2026, 8:00 AM EST - 4 months ago

Immunovant Earnings Call Transcript: Q3 2026


Immunovant Quarterly report: Q3 2026

Feb 6, 2026, 8:00 AM EST - 4 months ago

Immunovant Quarterly report: Q3 2026


Immunovant Earnings release: Q3 2026

Feb 6, 2026, 8:00 AM EST - 4 months ago

Immunovant Earnings release: Q3 2026


Immunovant reports Q3 EPS (61c), consensus (70c)

2026-02-06T12:05:33.000Z - 4 months ago

Immunovant reports Q3 EPS (61c), consensus (70c)


Immunovant Slides: Corporate presentation

Feb 6, 2026, 7:00 AM EST - 4 months ago

Immunovant Slides: Corporate presentation


Immunovant Earnings Call Transcript: Q2 2026

Nov 10, 2025, 8:00 AM EST - 7 months ago

Immunovant Earnings Call Transcript: Q2 2026


Immunovant Quarterly report: Q2 2026

Nov 10, 2025, 8:00 AM EST - 7 months ago

Immunovant Quarterly report: Q2 2026


Immunovant Earnings release: Q2 2026

Nov 10, 2025, 8:00 AM EST - 7 months ago

Immunovant Earnings release: Q2 2026


Immunovant Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 7 months ago

Immunovant Slides: Corporate Presentation


Immunovant Slides: Corporate Presentation

Sep 4, 2025, 7:00 AM EDT - 9 months ago

Immunovant Slides: Corporate Presentation


Immunovant Quarterly report: Q1 2026

Aug 11, 2025, 7:00 AM EDT - 10 months ago

Immunovant Quarterly report: Q1 2026


Immunovant Earnings release: Q1 2026

Aug 11, 2025, 7:00 AM EDT - 10 months ago

Immunovant Earnings release: Q1 2026


Immunovant Proxy statement: Proxy Filing

Jul 9, 2025, 8:00 AM EDT - 11 months ago

Immunovant Proxy statement: Proxy Filing


Immunovant Proxy statement: Proxy Filing

Jul 9, 2025, 8:00 AM EDT - 11 months ago

Immunovant Proxy statement: Proxy Filing


Immunovant Annual report: Q4 2025

May 29, 2025, 7:00 AM EDT - 1 year ago

Immunovant Annual report: Q4 2025


Immunovant Earnings release: Q4 2025

May 29, 2025, 7:00 AM EDT - 1 year ago

Immunovant Earnings release: Q4 2025


Immunovant Transcript: Investor Update

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Immunovant Transcript: Investor Update


Immunovant Press release: Investor Update

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Immunovant Press release: Investor Update


Immunovant Slides: Investor Update

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Immunovant Slides: Investor Update


Immunovant Transcript: Status Update

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Immunovant Transcript: Status Update


Immunovant Press release: Status Update

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Immunovant Press release: Status Update


Immunovant Slides: Status Update

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Immunovant Slides: Status Update


Immunovant Quarterly report: Q3 2025

Feb 6, 2025, 6:00 AM EST - 1 year ago

Immunovant Quarterly report: Q3 2025


Immunovant Earnings release: Q3 2025

Feb 6, 2025, 6:00 AM EST - 1 year ago

Immunovant Earnings release: Q3 2025


Immunovant Slides: FY 2025

Jan 14, 2025, 10:30 AM EST - 1 year ago

Immunovant Slides: FY 2025


Immunovant Quarterly report: Q2 2025

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunovant Quarterly report: Q2 2025


Immunovant Earnings release: Q2 2025

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunovant Earnings release: Q2 2025


Immunovant Transcript: Status Update

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Immunovant Transcript: Status Update


Immunovant Press release: Status Update

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Immunovant Press release: Status Update


Immunovant Slides: Status Update

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Immunovant Slides: Status Update


Immunovant Quarterly report: Q1 2025

Aug 6, 2024, 4:00 PM EDT - 2 years ago

Immunovant Quarterly report: Q1 2025


Immunovant Earnings release: Q1 2025

Aug 6, 2024, 4:00 PM EDT - 2 years ago

Immunovant Earnings release: Q1 2025


Immunovant Proxy statement: Proxy Filing

Jun 26, 2024, 8:00 AM EDT - 2 years ago

Immunovant Proxy statement: Proxy Filing


Immunovant Proxy statement: Proxy Filing

Jun 26, 2024, 8:00 AM EDT - 2 years ago

Immunovant Proxy statement: Proxy Filing


Immunovant Annual report: Q4 2024

May 29, 2024, 4:00 PM EDT - 2 years ago

Immunovant Annual report: Q4 2024


Immunovant Earnings release: Q4 2024

May 29, 2024, 4:00 PM EDT - 2 years ago

Immunovant Earnings release: Q4 2024


Immunovant Awarded U.S. Patent for IMVT-1402

Mar 12, 2024, 7:30 AM EDT - 2 years ago

Immunovant Awarded U.S. Patent for IMVT-1402


Immunovant Quarterly report: Q3 2024

Feb 12, 2024, 7:00 AM EST - 2 years ago

Immunovant Quarterly report: Q3 2024


Immunovant Earnings release: Q3 2024

Feb 12, 2024, 7:00 AM EST - 2 years ago

Immunovant Earnings release: Q3 2024


Immunovant Slides: FY 2024

Jan 9, 2024, 10:30 AM EST - 2 years ago

Immunovant Slides: FY 2024


Best Small-Cap Stocks to Buy for 2024 and Beyond

Dec 14, 2023, 1:24 PM EST - 2 years ago

Best Small-Cap Stocks to Buy for 2024 and Beyond

ARVN ASO BOOT FLYW GH PRVA RCKT


Immunovant Transcript: Study Update

Nov 28, 2023, 8:00 AM EST - 2 years ago

Immunovant Transcript: Study Update


Immunovant Press release: Study Update

Nov 28, 2023, 8:00 AM EST - 2 years ago

Immunovant Press release: Study Update


Immunovant Slides: Study Update

Nov 28, 2023, 8:00 AM EST - 2 years ago

Immunovant Slides: Study Update


Immunovant to Present at Upcoming Investor Conferences

Nov 13, 2023, 8:00 AM EST - 2 years ago

Immunovant to Present at Upcoming Investor Conferences


Immunovant Quarterly report: Q2 2024

Nov 9, 2023, 7:00 AM EST - 2 years ago

Immunovant Quarterly report: Q2 2024


Immunovant Earnings release: Q2 2024

Nov 9, 2023, 7:00 AM EST - 2 years ago

Immunovant Earnings release: Q2 2024


Immunovant Transcript: Study Result

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Immunovant Transcript: Study Result


Immunovant Press release: Study Result

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Immunovant Press release: Study Result


Immunovant Quarterly report: Q1 2024

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Immunovant Quarterly report: Q1 2024


Immunovant Earnings release: Q1 2024

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Immunovant Earnings release: Q1 2024


Immunovant Proxy statement: Proxy Filing

Jun 26, 2023, 8:00 AM EDT - 3 years ago

Immunovant Proxy statement: Proxy Filing


Immunovant Proxy statement: Proxy Filing

Jun 26, 2023, 8:00 AM EDT - 3 years ago

Immunovant Proxy statement: Proxy Filing


Immunovant Annual report: Q4 2023

May 22, 2023, 7:00 AM EDT - 3 years ago

Immunovant Annual report: Q4 2023


Immunovant Earnings release: Q4 2023

May 22, 2023, 7:00 AM EDT - 3 years ago

Immunovant Earnings release: Q4 2023


Immunovant Quarterly report: Q3 2023

Feb 3, 2023, 7:00 AM EST - 3 years ago

Immunovant Quarterly report: Q3 2023


Immunovant Earnings release: Q3 2023

Feb 3, 2023, 7:00 AM EST - 3 years ago

Immunovant Earnings release: Q3 2023


Immunovant Transcript: Fireside Chat

Dec 8, 2022, 10:00 AM EST - 3 years ago

Immunovant Transcript: Fireside Chat


Immunovant Quarterly report: Q2 2023

Nov 4, 2022, 8:00 AM EDT - 3 years ago

Immunovant Quarterly report: Q2 2023


Immunovant Earnings release: Q2 2023

Nov 4, 2022, 8:00 AM EDT - 3 years ago

Immunovant Earnings release: Q2 2023


Immunovant Transcript: Investor Day 2022

Sep 28, 2022, 11:15 AM EDT - 4 years ago

Immunovant Transcript: Investor Day 2022


Immunovant Press release: FY 2022

Sep 28, 2022, 11:15 AM EDT - 4 years ago

Immunovant Press release: FY 2022


Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn

Sep 28, 2022, 10:45 AM EDT - 4 years ago

Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn


Immunovant to Present at Roivant Investor Day on September 28th

Sep 21, 2022, 8:00 AM EDT - 4 years ago

Immunovant to Present at Roivant Investor Day on September 28th


NVDAMillionaire
NVDAMillionaire Jun. 5 at 6:34 PM
$IMVT Great piece that accurately captures IMVT's current position. So if you want to refresh your understanding of IMVT or learn about IMVT for the first time, this is essential reading. https://everyticker.com/quote/IMVT/analysis/immunovant-s-7-billion-bet-can-imvt-1402-s-best-in-class-profile-justify-a-pipeline-in-a-product-valuation-nasdaq-imvt
0 · Reply
anachartanalyst
anachartanalyst May. 26 at 2:01 PM
$IMVT https://anachart.com/wp-content/uploads/2026/05/1779804088_soc-img.jpg
0 · Reply
jcooptechit
jcooptechit May. 22 at 4:56 PM
$CUE | CATALYST TIMELINE IS STACKING 🔥 Cue Biopharma is entering a major value-driving window with multiple 2H 2026 milestones ahead. ▫️ CUE-221 Phase 2 China data expected 2H 2026 ▫️ Food allergy IND amendment planned ▫️ CUE-401 IND filing expected 2H 2026 ▫️ Phase 1 first-in-human targeted by year-end ▫️ $7.5M Boehringer milestone validates the platform ▫️ $30M financing strengthens execution This is now a clinical-stage immunology/allergy story with big catalysts lining up. Keep CUE on close watch going into data. 🧐 Communicated - Disclaimer: https://stockresearchtoday.com/cue/ Sector Peers: $IMVT $KYTX $CABA $TERN
1 · Reply
ShadowBanningIsBad
ShadowBanningIsBad May. 22 at 4:32 PM
$MS $DDOG $IMVT $NXPI $VLO Remember sell high buy low.
1 · Reply
Clev21
Clev21 May. 21 at 7:24 PM
$IMVT she’s consolidating right now. Big move coming after hours
0 · Reply
KenCowboys
KenCowboys May. 21 at 2:59 PM
$IMVT trimmed just a little yesterday at $34 but will def add some back if it drops further
0 · Reply
secondideas
secondideas May. 21 at 2:51 PM
$IMVT dilution offering
0 · Reply
Quantumup
Quantumup May. 21 at 2:25 PM
TD Cowen⬆️ $ROIV's PT to $41 and reiterated at Buy. $IMVT $ABUS TD Cowen said—IMVT-1402 Shines In D2T RA, Many More Catalysts On Deck IMVT-1402 toplined impressive Ph2b D2T RA data w/ACR20 of 73%, ACR50 of 55%, and ACR70 of 36%. Brepo in CS received FDA BTD, on track to initiate Ph3 in H2:26. Brepo DM launch in late Sept, with our KOL anticipating bolus at launch. Next catalysts: brepo Ph3 data in NIU & mosli Ph2b data in PH-ILD in H2:26. Commercial launch of IMVT-1402 in Graves' & D2T RA expected in '27/28. New PT $41 (+$3).
2 · Reply
GlobalMarketBulletin
GlobalMarketBulletin May. 21 at 10:46 AM
$IMVT Immunovant Inc. (NASDAQ: IMVT) exploded more than 35% after strong IMVT-1402 rheumatoid arthritis trial results excited biotech investors. With bullish analyst support and more updates expected in 2026, IMVT suddenly became one of the hottest healthcare stocks to watch. https://globalmarketbulletin.com/can-immunovant-imvt-turn-its-rheumatoid-arthritis-trial-win-into-a-bigger-fda-story/
0 · Reply
Quantumup
Quantumup May. 21 at 10:33 AM
BofA⬆️ $IMVT's PT to $43 and reiterated at Buy $ROIV $ARGX JNJ LLY - INCY ABBV UCBJY AZN BofA said: We raise our Immunovant (IMVT) PO to $43/sh (from $32) on a higher peak sales outlook for IMVT-1402, now $6.8BN (vs. $5.5BN prior), driven by greater contribution from GD & D2T RA-both large 'white-space' TAMs. Our revision incorporates DT2A derisking from Period 1 data (reported yesterday) and potential upside from upcoming pivotal readouts. We are most bullish on GD (50% of valuation) given strong prior data and unmet need. While CLE/SJD are sizable markets, we assign lower value due to higher clinical/competitive risk. We also reduce 1402 peak sales in FcRn-entrenched markets (MG, CIDP). See Exhibit 1 for updated risk-adjusted SOTP DCF. We reiterate Buy as in our view 1402's opportunity remains underappreciated.
0 · Reply
GlobalMarketBulletin
GlobalMarketBulletin May. 21 at 10:06 AM
$ALAB $IMVT $NVTS $XNDU $TE Wall Street’s latest rally created some huge winners, and these 5 stocks stood out with powerful gains, heavy trading activity, and company-specific catalysts investors are watching closely. https://globalmarketbulletin.com/top-5-stocks-delivering-big-time-gains-today/
0 · Reply
d_risk
d_risk May. 21 at 9:42 AM
$IMVT - Immunovant Inc - 10K - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +51.5% above peer average (42,389 vs 27,983 across 639 peers). IMVT flags heightened risk from non-predictive early data, fierce IMVT‑1402 competition across MG/SjD/GD/CIDP, heavy build‑out or reliance on third‑party commercialization, expanding anti-kickback/FCA and pricing regulation, and new BIOSECURE Act CMO restrictions that could disrupt its supply chain. #Biopharmaceuticals #AutoimmuneDiseases #RegulatoryRisk #CompetitivePressure #SupplyChainDisruption 🟢 Added 🟠 Removed https://d-risk.ai/IMVT/10-K/2026-05-20
0 · Reply
RunnerSignals
RunnerSignals May. 21 at 3:48 AM
stock IQ surge (May 20) $IMVT IQ score 3.32 to 4.82 arthritis trial data. 35% on 12x volume $URBN IQ score 1.81 to 5.00 record q1 earnings beat. cleanest setup $KURA IQ score confirmed 5.00 second session. uptrend intact full breakdown https://stocksrunner.com/news/2026-05-20-stock-iq-surge-top-signal-movers
0 · Reply
TrustButVerifi
TrustButVerifi May. 21 at 1:07 AM
$VKTX $IMVT $SLS I bought IMVT for my kids 3 years ago and never looked at it til today! Viking will have the most explosive upside of any bio in history! Mark this post !
0 · Reply
Spicy_Trade
Spicy_Trade May. 20 at 11:37 PM
Immunovant, Inc. ( $IMVT )SpicyTrade - Daily Stock Analysis https://youtu.be/5ceIfCJ3E7Y?si=I0c0WA25PtZ_1nS-
0 · Reply
Doozio
Doozio May. 20 at 11:36 PM
$IMVT imagine getting MNDY 🐑 d. Bums.
0 · Reply
topstockalerts
topstockalerts May. 20 at 9:24 PM
Top Gainers PT2 $MTVA $MWC $PETZ $MLGO $IMVT
0 · Reply
topstockalerts
topstockalerts May. 20 at 9:21 PM
$IMVT something about this tape feels very controlled.
0 · Reply
FibonacciTrader_
FibonacciTrader_ May. 20 at 9:12 PM
Tech, finance, energy, and semis all showing serious strength today — these names touched fresh 52-week highs: $MS – Banking heavyweight, market confidence showing $DDOG – Cloud monitoring king, growth story intact $IMVT – Biotech momentum surging, watch for catalysts $NXPI – Semiconductor exposure firing on all cylinders $VLO – Energy rally fueled by tight crude + refinery margins Market breadth is wide, but runs like this can shake weak hands fast. Are you going to miss out again?
0 · Reply
mikesterz7
mikesterz7 May. 20 at 8:52 PM
$IMVT Immunovant posted encouraging Phase 2 data for its rheumatoid arthritis therapy, even as fourth-quarter net loss came in wider than expected.
1 · Reply
topstockalerts
topstockalerts May. 20 at 8:03 PM
$IMVT is anyone else surprised by how well this is behaving?
0 · Reply
MorganHoratio
MorganHoratio May. 20 at 7:59 PM
Today, the following 50 stocks all hit a 52-week high at some point:(6-10) Morgan Stanley $MS Datadog $DDOG Immunovant $IMVT NXP Semiconductors $NXPI Valero Energy $VLO 🔥 The 52-week high club is officially rotating! This isn't just a momentum tech chase; it’s a broad-market stampede into rock-solid fundamental strength. The divergence here is key: $DDOG just crossed its first-ever billion-dollar quarter on explosive AI infrastructure demand, while $NXPI punched through local ceilings on accelerating automotive and industrial silicon trends. Even more telling is the institutional rush into defensive cash flows—Wall Street titan $MS and refining king $VLO are hitting fresh highs simultaneously. This proves smart money is strictly chasing high-conviction EPS expansion. When megacaps, energy, and software rally together, where is the real macro alpha hiding? Are you chasing these breakouts or waiting for a macro dip? Drop your bets below! 👇
0 · Reply